アトピー性皮膚炎治療薬の世界市場:薬物クラス別、流通チャンネル別

• 英文タイトル:Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027「アトピー性皮膚炎治療薬の世界市場:薬物クラス別、流通チャンネル別」(市場規模、市場予測)調査レポートです。• レポートコード:TPM-NV194
• 出版社/出版日:Transparency Market Research / 2019年10月
• レポート形態:英文、PDF、145ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥625,860 (USD5,795)▷ お問い合わせ
  Multi User¥949,860 (USD8,795)▷ お問い合わせ
  Global Site License¥1,273,860 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、アトピー性皮膚炎治療薬の世界市場について調べ、アトピー性皮膚炎治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリア皮膚軟化剤、CNI免疫抑制剤、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・アトピー性皮膚炎治療薬の市場概要
・アトピー性皮膚炎治療薬の市場動向
・アトピー性皮膚炎治療薬の世界市場規模・予測
・アトピー性皮膚炎治療薬市場:薬物クラス別(コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリア皮膚軟化剤、CNI免疫抑制剤、その他)
・アトピー性皮膚炎治療薬市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

According to a study published by BioMed Central, U.K – an electronic-only medical journal, it was found that, on a global level, ~15 – 20% children and ~1 – 3% adults suffer from atopic dermatitis (AD). The growing prevalence of this disease has triggered the demand for efficacious drugs in the atopic dermatitis drugs market.

Biologic drugs are projected for exponential growth during the forecast period. In 2018, biologic drugs accounted for the highest market share of ~42%, and continue to dominate the market share with a projected value of ~77% in 2027. Thus, it is evident that, healthcare companies in the atopic dermatitis drugs market are increasing research & development activities to improve the efficacy of biologic drugs in order to provide instant relief for patients.

Since atopic dermatitis has a high risk of recurrence, healthcare companies in the atopic dermatitis drugs market are identifying drugs that improve the functioning of the immune system by helping to fight off bacteria and viruses. For instance, in August 2019, Sanofi – a French multinational pharmaceutical company, announced the approval of Dupixent® (dupilumab) – a biologic drug to treat moderate-to-severe atopic dermatitis, by the European Commission.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atopic Dermatitis Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Definition

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook

5.1. Disease Epidemiology

5.2. Pipeline Analysis

5.3. Recent Development

6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class

6.1. Introduction & Definition

6.2. Market Value Forecast by Drug Class, 2017–2027

6.2.1. Corticosteroids

6.2.2. PDE4 Inhibitors

6.2.3. Biologics

6.2.4. Skin Barrier Emollients

6.2.5. CNI Immunosuppressants

6.2.6. Others

6.3. Market Attractiveness by Drug Class

7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel

7.1. Introduction & Definition

7.2. Market Value Forecast by Distribution Channel, 2017–2027

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

7.3. Market Attractiveness by Distribution Channel

8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region

8.1. Key Findings

8.2. Market Value Forecast by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness by Country/Region

9. North America Atopic Dermatitis Drugs Market Analysis and Forecast

9.1. Introduction

9.2. Market Value Forecast by Drug Class, 2017–2027

9.2.1. Corticosteroids

9.2.2. PDE4 Inhibitors

9.2.3. Biologics

9.2.4. Skin Barrier Emollients

9.2.5. CNI Immunosuppressants

9.2.6. Others

9.3. Market Value Forecast by Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Market Value Forecast by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Distribution Channel

9.5.3. By Country

10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast

10.1. Introduction

10.2. Market Value Forecast by Drug Class, 2017–2027

10.2.1. Corticosteroids

10.2.2. PDE4 Inhibitors

10.2.3. Biologics

10.2.4. Skin Barrier Emollients

10.2.5. CNI Immunosuppressants

10.2.6. Others

10.3. Market Value Forecast by Distribution Channel, 2017–2027

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Market Value Forecast by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis

10.5.1. By Drug Class

10.5.2. By Distribution Channel

10.5.3. By Country/Sub-region

11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast

11.1. Introduction

11.2. Market Value Forecast by Drug Class, 2017–2027

11.2.1. Corticosteroids

11.2.2. PDE4 Inhibitors

11.2.3. Biologics

11.2.4. Skin Barrier Emollients

11.2.5. CNI Immunosuppressants

11.2.6. Others

11.3. Market Value Forecast by Distribution Channel, 2017–2027

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Market Value Forecast by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis

11.5.1. By Drug Class

11.5.2. By Distribution Channel

11.5.3. By Country/Sub-region

12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast

12.1. Introduction

12.2. Market Value Forecast by Drug Class, 2017–2027

12.2.1. Corticosteroids

12.2.2. PDE4 Inhibitors

12.2.3. Biologics

12.2.4. Skin Barrier Emollients

12.2.5. CNI Immunosuppressants

12.2.6. Others

12.3. Market Value Forecast by Distribution Channel, 2017–2027

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Market Value Forecast by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Distribution Channel

12.5.3. By Country/Sub-region

13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast

13.1. Introduction

13.2. Market Value Forecast by Drug Class, 2017–2027

13.2.1. Corticosteroids

13.2.2. PDE4 Inhibitors

13.2.3. Biologics

13.2.4. Skin Barrier Emollients

13.2.5. CNI Immunosuppressants

13.2.6. Others

13.3. Market Value Forecast by Distribution Channel, 2017–2027

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Market Value Forecast by Country/Sub-region, 2017–2027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis

13.5.1. By Drug Class

13.5.2. By Distribution Channel

13.5.3. By Country/Sub-region

14. Competitive Landscape

14.1. Company Profiles

14.1.1. Mylan N.V.

14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.1.2. Product Portfolio

14.1.1.3. SWOT Analysis

14.1.1.4. Strategic Overview

14.1.1.5. Financial Overview

14.1.2. Pfizer, Inc.

14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.2.2. Product Portfolio

14.1.2.3. SWOT Analysis

14.1.2.4. Strategic Overview

14.1.2.5. Financial Overview

14.1.3. LEO Pharma A/S

14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.3.2. Product Portfolio

14.1.3.3. SWOT Analysis

14.1.3.4. Strategic Overview

14.1.3.5. Financial Overview

14.1.4. Teva Pharmaceutical Industries Ltd

14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.4.2. Product Portfolio

14.1.4.3. SWOT Analysis

14.1.4.4. Strategic Overview

14.1.4.5. Financial Overview

14.1.5. Sanofi

14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.5.2. Product Portfolio

14.1.5.3. SWOT Analysis

14.1.5.4. Strategic Overview

14.1.5.5. Financial Overview

14.1.6. Novartis AG

14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.1.6.2. Product Portfolio

14.1.6.3. SWOT Analysis

14.1.6.4. Strategic Overview

14.1.6.5. Financial Overview




• 英文レポート名:Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027
• 日本語訳:アトピー性皮膚炎治療薬の世界市場:薬物クラス別、流通チャンネル別
• レポートコード:TPM-NV194お問い合わせ(見積依頼・ご注文・質問)